Literature DB >> 3279941

Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes.

M R Taskinen1, T Kuusi, E Helve, E A Nikkilä, H Yki-Järvinen.   

Abstract

To study the effects of rigorous insulin therapy on serum lipoproteins in patients with noninsulin-dependent diabetes not controlled with oral agents only, we measured serum lipoproteins, apoproteins, lipolytic enzymes, and glucose disposal using an insulin clamp technique before and after 4 weeks of insulin therapy. Lipoproteins were isolated by ultracentrifugation and high density lipoprotein (HDL) subfractions, by rate-zonal density gradient ultracentrifugation. The group included 11 women and eight men (age 58 +/- 1 years and RBW 125 +/- 4%). Body weight, glycosylated hemoglobin, mean diurnal glucose, plasma free insulin, and glucose uptake (M-value) were 75 vs. 76 kg; 11.9 vs. 8.9%; 234 vs. 124 mg/dl; 12 vs. 27 microU/ml; and 5.0 +/- 0.4 vs. 7.1 +/- 0.6 mg/kg/min before and after insulin therapy, respectively. After insulin therapy there was a decrease of very low density lipoprotein (VLDL) triglyceride (-60%, p less than 0.001) but an increase of HDL2 cholesterol (+21%, p less than 0.001); HDL2 phospholipids (+38%, p less than 0.001); HDL2 proteins (+23%, p less than 0.01); and HDL2 mass (127 +/- 11 vs. 158 +/- 12 mg/dl, p less than 0.001). There was a decrease of HDL3 cholesterol (-13%, p less than 0.05); HDL3 phospholipids (-16%, p less than 0.05); HDL3 proteins (-18%, p less than 0.001); and HDL3 mass (179 +/- 6 vs. 146 +/- 6, p less than 0.01). Zonal profiles showed a redistribution of particles from HDL3 to HDL2. Serum apo A-I increased (p less than 0.05), apo A-II remained constant, but apo B decreased (-29%, p less than 0.001). The most marked change during insulin therapy was a 2.3-fold increase in adipose tissue lipoprotein lipase (LPL) activity (p less than 0.001). The changes of VLDL and HDL subfractions were not explained by respective changes of the blood glucose, free insulin, or M-value. The data indicate that intensive insulin therapy induces antiatherogenic changes in serum lipids and lipoproteins and suggest that the induction of LPL by insulin is the major factor responsible for redistribution of HDL particles from HDL3 to HDL2.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3279941     DOI: 10.1161/01.atv.8.2.168

Source DB:  PubMed          Journal:  Arteriosclerosis        ISSN: 0276-5047


  38 in total

Review 1.  Coronary heart disease in diabetes mellitus--antecedents and associations.

Authors:  P H Winocour
Journal:  Postgrad Med J       Date:  1991-10       Impact factor: 2.401

2.  Role of candidate genes in the lipid responses to intensified treatment in Type 2 diabetes.

Authors:  O Ukkola; J Salonen; Y Antero Kesäniemi
Journal:  J Endocrinol Invest       Date:  2005-11       Impact factor: 4.256

3.  Elevated triglyceride-rich lipoproteins in diabetes. A study of apolipoprotein B-48.

Authors:  A Curtin; P Deegan; D Owens; P Collins; A Johnson; G H Tomkin
Journal:  Acta Diabetol       Date:  1996-09       Impact factor: 4.280

4.  Composition and lipid spatial distribution of HDL particles in subjects with low and high HDL-cholesterol.

Authors:  Laxman Yetukuri; Sanni Söderlund; Artturi Koivuniemi; Tuulikki Seppänen-Laakso; Perttu S Niemelä; Marja Hyvönen; Marja-Riitta Taskinen; Ilpo Vattulainen; Matti Jauhiainen; Matej Oresic
Journal:  J Lipid Res       Date:  2010-04-29       Impact factor: 5.922

5.  Regulation of low-density lipoprotein particle size distribution in NIDDM and coronary disease: importance of serum triglycerides.

Authors:  S Lahdenperä; M Syvänne; J Kahri; M R Taskinen
Journal:  Diabetologia       Date:  1996-04       Impact factor: 10.122

6.  Insulin and its analogue glargine do not affect viability and proliferation of human coronary artery endothelial and smooth muscle cells.

Authors:  K Staiger; H Staiger; M A Schweitzer; E Metzinger; B Balletshofer; H-U Häring; M Kellerer
Journal:  Diabetologia       Date:  2005-08-03       Impact factor: 10.122

7.  Changes of lipolytic enzymes cluster with insulin resistance syndrome. Botnia Study Group.

Authors:  P Knudsen; J Eriksson; S Lahdenperä; J Kahri; L Groop; M R Taskinen
Journal:  Diabetologia       Date:  1995-03       Impact factor: 10.122

8.  Serum saturated fatty acids containing triacylglycerols are better markers of insulin resistance than total serum triacylglycerol concentrations.

Authors:  A Kotronen; V R Velagapudi; L Yetukuri; J Westerbacka; R Bergholm; K Ekroos; J Makkonen; M-R Taskinen; M Oresic; H Yki-Järvinen
Journal:  Diabetologia       Date:  2009-02-13       Impact factor: 10.122

9.  Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects.

Authors:  M I Uusitupa; L K Niskanen; O Siitonen; E Voutilainen; K Pyörälä
Journal:  Diabetologia       Date:  1993-11       Impact factor: 10.122

10.  ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan.

Authors:  Anne Hiukka; Marcus Ståhlman; Camilla Pettersson; Malin Levin; Martin Adiels; Susanne Teneberg; Eeva S Leinonen; Lillemor Mattsson Hultén; Olov Wiklund; Matej Oresic; Sven-Olof Olofsson; Marja-Riitta Taskinen; Kim Ekroos; Jan Borén
Journal:  Diabetes       Date:  2009-06-05       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.